April 27 (Reuters) - Gilead Sciences Inc said on Friday its three-drug regimen to treat HIV infection was recommended for approval by a panel of the European Medicines Agency, paving the way for the biotech company to capture more sales in the multibillion-dollar market.
Gilead's three-drug HIV regimen wins European panel approval
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться